Search
Labetuzumab
go.drugbank.com/drugs/DB05097InvestigationalLabetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy.
Gemcabene
go.drugbank.com/drugs/DB05123InvestigationalGemcabene is a new drug that lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C).
Aminocandin
go.drugbank.com/drugs/DB05128ExperimentalAminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
Tanespimycin
go.drugbank.com/drugs/DB05134InvestigationalTanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).
Vibriolysin
go.drugbank.com/drugs/DB05135ExperimentalVibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. … It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.
XL820
go.drugbank.com/drugs/DB05146InvestigationalXL820 is a solid. … receptor beta (PDGFR), mast/stem cell growth factor receptor KIT, vascular endothelial growth factor receptor 2, and platelet-derived growth factor receptor alpha, clinically validated targets implicated in a
TST10088
go.drugbank.com/drugs/DB05151ExperimentalTST10088 is a recombinant variant of a plant toxin belonging to the family of class II ribosome inactivating proteins. … TST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis
Topsalysin
go.drugbank.com/drugs/DB05160InvestigationalTopsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
LY2275796
go.drugbank.com/drugs/DB05165InvestigationalLY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
APD668
go.drugbank.com/drugs/DB05166ExperimentalAPD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated